Noesis Capital Mangement Trimmed Its Amdocs LTD (DOX) Holding; Trinity Biotech plc (TRIB) Had 2 Bulls

February 12, 2018 - By Adrian Erickson

Among 4 analysts covering Trinity Biotech (NASDAQ:TRIB), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Trinity Biotech had 5 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Buy” rating by TH Capital given on Wednesday, July 29. The stock has “Equal-Weight” rating by Stephens on Wednesday, October 5. The rating was downgraded by Craig Hallum on Friday, October 23 to “Hold”. The firm has “Outperform” rating given on Thursday, September 3 by Raymond James. See Trinity Biotech plc (NASDAQ:TRIB) latest ratings:

Noesis Capital Mangement Corp decreased Amdocs Ltd (DOX) stake by 9.41% reported in 2017Q3 SEC filing. Noesis Capital Mangement Corp sold 11,265 shares as Amdocs Ltd (DOX)’s stock rose 6.65%. The Noesis Capital Mangement Corp holds 108,485 shares with $6.98 million value, down from 119,750 last quarter. Amdocs Ltd now has $9.35 billion valuation. The stock decreased 0.23% or $0.15 during the last trading session, reaching $65. About 464,915 shares traded. Amdocs Limited (NASDAQ:DOX) has risen 13.40% since February 12, 2017 and is uptrending. It has underperformed by 3.30% the S&P500.

The stock increased 0.73% or $0.04 during the last trading session, reaching $5.55. About 4,699 shares traded. Trinity Biotech plc (NASDAQ:TRIB) has declined 52.33% since February 12, 2017 and is downtrending. It has underperformed by 69.03% the S&P500.

Trinity Biotech plc acquires, develops, makes, and markets medical diagnostic products for the clinical laboratory and point-of-care divisions of the diagnostic market. The company has market cap of $128.23 million. The firm offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes. It currently has negative earnings. It also develops, makes, and distributes products in the enzyme-linked immunosorbent, western blot, and cytotoxicity assay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia.

Among 7 analysts covering Amdocs (NASDAQ:DOX), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. Amdocs had 21 analyst reports since July 30, 2015 according to SRatingsIntel. On Thursday, December 14 the stock rating was maintained by Oppenheimer with “Buy”. On Wednesday, January 31 the stock rating was maintained by Stifel Nicolaus with “Buy”. Stifel Nicolaus maintained the shares of DOX in report on Thursday, September 14 with “Buy” rating. The firm has “Buy” rating given on Thursday, January 28 by Bank of America. The rating was maintained by Oppenheimer on Tuesday, September 5 with “Buy”. The rating was maintained by Jefferies on Friday, June 16 with “Hold”. Stifel Nicolaus maintained it with “Buy” rating and $63 target in Thursday, July 30 report. The rating was downgraded by Barclays Capital on Thursday, November 12 to “Equal Weight”. Citigroup maintained Amdocs Limited (NASDAQ:DOX) rating on Wednesday, July 27. Citigroup has “Buy” rating and $66 target. The firm earned “Buy” rating on Wednesday, January 31 by Oppenheimer.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>